Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...

The FDA has granted approval to Akeso's differentiated programmed cell death protein 1 (PD-1) monoclonal antibody, penpulimab ...

An investigational monoclonal antibody called bentracimab can safely and effectively reverse potentially catastrophic bleeding complications linked to ticagrelor, a common drug used to treat patients ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the U.S. Food and Drug Administration (FDA) has approved its differentiated PD-1 monoclonal antibody, penpulimab-kcqx, in ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the U.S. Food and Drug Administration (FDA) ...

During a live event, Jack Khouri, MD, discussed options for patients with multiple myeloma after relapse and choices to ...

Abu Dhabi has taken a groundbreaking step in personalised healthcare by integrating APOE genetic testing for Alzheimer’s ...

Groundbreaking treatment enhances the immune system's ability to fight cancer Holy Cross Health now offers bispecific therapy ...

Monoclonal antibody therapy is complicated by the potential for the human immune system to form antibodies to these drugs. Antibodies can be formed to the Fv and Fc regions or to murine epitopes.